Skip Navigation

COVID-19: We are vaccinating patients ages 12+. Learn more:

Vaccines, Boosters & 3rd Doses | Testing | Patient Care | Visitor Guidelines | Coronavirus | Self-Checker | Email Alerts

 

Philips Respironics issued a recall for some CPAP and BiLevel PAP devices and mechanical ventilators. Learn more.

 

PRRT Treatment Information

Patients with gastroenteropancreatic neuroendocrine tumors (GEP-NETs) receiving Lutathera® ([177Lu]DOTATATE) at Johns Hopkins Hospital must first be evaluated by a medical oncologist at Johns Hopkins for consultation. The medical oncologist will review the case with the Johns Hopkins nuclear medicine team. If all are in agreement that peptide receptor radionuclide therapy (PRRT) with Lutathera® is appropriate, the nuclear medicine team will pursue the additional required assessments. Patients must have somatostatin receptor-positive GEP-NETs, with a positive result on a somatostatin receptor-specific imaging study, e.g., NETSPOT™ ([68Ga]DOTATATE PET/CT, documented prior to therapy.

The Johns Hopkins Hospital nuclear medicine team will obtain insurance preauthorization prior to scheduling the first PRRT treatment. Patients, or their referring physician, may schedule the initial consultation. A copy of the patient’s medical records will be requested by the nuclear medicine team, including clinic notes, the pathology report confirming diagnosis, imaging, and laboratory tests.

To schedule the initial consultation, please contact: Avery Spitz RN, MSN,
Phone: 443-253-3894 
Fax: 410-955-0326
Email: aspitz2@jhmi.edu

Insurance questions will be addressed at the time of scheduling the first PRRT treatment.

back to top button